CCR 20周年评论：存活——抗凋亡蛋白与乳腺癌
CCR 20th Anniversary commentary: stayin' alive-antiapoptotic proteins and breast cancer.
作者信息
Yee Douglas
机构信息
Masonic Cancer Center, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
出版信息
Clin Cancer Res. 2015 Feb 15;21(4):665-6. doi: 10.1158/1078-0432.CCR-14-2548.
Abstract
The control of cell death involves a complex interaction of multiple proteins. In a study published in the January 1, 2000, issue of Clinical Cancer Research, Tanaka and colleagues demonstrated that one of the proapoptotic proteins, survivin, was frequently expressed in breast cancer. In the subsequent years, effectors of apoptosis have translated into important prognostic indicators and potential therapeutic targets.
摘要
细胞死亡的调控涉及多种蛋白质的复杂相互作用。在2000年1月1日发表于《临床癌症研究》杂志的一项研究中，田中及其同事证明，一种促凋亡蛋白survivin在乳腺癌中经常表达。在随后的几年里，凋亡效应蛋白已转化为重要的预后指标和潜在的治疗靶点。
相似文献
1
CCR 20th Anniversary commentary: stayin' alive-antiapoptotic proteins and breast cancer.CCR 20周年评论：存活——抗凋亡蛋白与乳腺癌
Clin Cancer Res. 2015 Feb 15;21(4):665-6. doi: 10.1158/1078-0432.CCR-14-2548.
2
CCR 20th Anniversary Commentary: Divide and Conquer-Breast Cancer Subtypes and Response to Therapy.CCR 20 周年述评：分而治之——乳腺癌亚型与治疗反应。
Clin Cancer Res. 2015 Aug 15;21(16):3575-7. doi: 10.1158/1078-0432.CCR-14-3121.
3
CCR 20th Anniversary Commentary: Chimeric Antigen Receptors-From Model T to the Tesla.CCR 20 周年述评：嵌合抗原受体——从 T 型车到特斯拉。
Clin Cancer Res. 2015 Jul 15;21(14):3099-101. doi: 10.1158/1078-0432.CCR-14-2560.
4
CCR 20th Anniversary Commentary: Determining a Pharmacokinetic/Pharmacodynamic Relationship for Sunitinib—A Look Back.CCR 20 周年述评：西尼替尼的药代动力学/药效学关系的确定——回顾过去。
Clin Cancer Res. 2015 Jun 1;21(11):2415-7. doi: 10.1158/1078-0432.CCR-14-2557.
5
CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel-How Far Science Has Come.CCR 20 周年述评：为白蛋白结合型紫杉醇奠定舞台——科学的发展之路。
Clin Cancer Res. 2015 May 1;21(9):1975-7. doi: 10.1158/1078-0432.CCR-14-2554.
6
CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer--Where Did It Start and Where Are We Now?CCR 20 周年述评：乳腺癌的基因表达特征——它从何而来，我们现在在哪里？
Clin Cancer Res. 2015 Nov 1;21(21):4743-6. doi: 10.1158/1078-0432.CCR-14-3127.
7
Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.BIM 诱导和生存素下调在曲妥珠单抗诱导 HER2 扩增乳腺癌细胞凋亡中的作用。
Oncogene. 2011 Sep 29;30(39):4097-106. doi: 10.1038/onc.2011.111. Epub 2011 Apr 18.
8
miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.微小RNA-218靶向存活素并调节乳腺癌对化疗药物的耐药性。
Breast Cancer Res Treat. 2015 Jun;151(2):269-80. doi: 10.1007/s10549-015-3372-9. Epub 2015 Apr 22.
9
ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer.表皮生长因子受体 2（ERBB2）在淋巴结阴性乳腺癌中诱导 Bcl-2 家族成员的抗凋亡表达模式。
Clin Cancer Res. 2010 Jan 15;16(2):451-60. doi: 10.1158/1078-0432.CCR-09-1617. Epub 2010 Jan 12.
10
CCR 20th Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping.CCR 20 周年述评：乳腺癌分子分型的发展。
Clin Cancer Res. 2015 Apr 15;21(8):1779-81. doi: 10.1158/1078-0432.CCR-14-2552.
本文引用的文献
1
Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.使用生存素反义寡核苷酸LY2181308联合多西他赛治疗非小细胞肺癌患者二线治疗时通过肿瘤大小变化评估其抗肿瘤活性：一项随机开放标签II期研究
J Thorac Oncol. 2014 Nov;9(11):1704-8. doi: 10.1097/JTO.0000000000000285.
2
A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer.一项联合 LY2181308 钠（生存素反义寡核苷酸）与一线多西他赛/泼尼松治疗去势抵抗性前列腺癌患者的随机 2 期研究。
Eur Urol. 2014 Mar;65(3):516-20. doi: 10.1016/j.eururo.2013.10.039. Epub 2013 Nov 6.
3
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.塞帕替尼溴化物（YM155，生存素抑制剂）联合紫杉醇和顺铂治疗晚期非小细胞肺癌的 I/II 期研究。
Ann Oncol. 2013 Oct;24(10):2601-2606. doi: 10.1093/annonc/mdt249. Epub 2013 Jul 14.
4
Treat cancers by targeting survivin: just a dream or future reality?通过靶向存活素治疗癌症：只是一个梦想还是未来的现实？
Cancer Treat Rev. 2013 Nov;39(7):802-11. doi: 10.1016/j.ctrv.2013.02.002. Epub 2013 Feb 28.
5
Targeting survivin in cancer.针对癌症中的存活素。
Cancer Lett. 2013 May 28;332(2):225-8. doi: 10.1016/j.canlet.2012.03.005. Epub 2012 Mar 9.
6
Treatment of HER2-positive breast cancer: current status and future perspectives.人表皮生长因子受体 2 阳性乳腺癌的治疗：现状与未来展望。
Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32. doi: 10.1038/nrclinonc.2011.177.
7
A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma.多中心 II 期评估小分子存活素抑制剂 YM155 治疗不可切除的 III 或 IV 期黑色素瘤患者的疗效。
Invest New Drugs. 2011 Feb;29(1):161-6. doi: 10.1007/s10637-009-9333-6. Epub 2009 Oct 15.
8
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.一种用于预测他莫昔芬治疗的、淋巴结阴性乳腺癌复发的多基因检测方法。
N Engl J Med. 2004 Dec 30;351(27):2817-26. doi: 10.1056/NEJMoa041588. Epub 2004 Dec 10.
9
Expression of survivin and its relationship to loss of apoptosis in breast carcinomas.生存素在乳腺癌中的表达及其与细胞凋亡缺失的关系。
Clin Cancer Res. 2000 Jan;6(1):127-34.
10
S-phase fraction and breast cancer--a decade of experience.S期分数与乳腺癌——十年经验
Breast Cancer Res Treat. 1998;51(3):255-65. doi: 10.1023/a:1006188512927.
Zotero 插件